Creating targeted treatments for HIV/AIDS medications
Developing Selective Inhibitors and Probes for Concentrative Nucleoside Transporters
This study is looking at ways to make HIV treatments safer and more effective by creating new tools that help transport important medications in the body, which could lead to fewer side effects for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rosalind Franklin Univ of Medicine & Sci NIH-funded |
| Lab location | 1 site (North Chicago, United States) |
| Project ID | NIH-10940330 on NIH RePORTER |
What this research studies
This research focuses on developing selective inhibitors and probes for concentrative nucleoside transporters, which are crucial for the transport of nucleoside drugs used in HIV/AIDS therapy. By optimizing the therapeutic outcomes of nucleoside reverse transcriptase inhibitors (NRTIs), the study aims to reduce the adverse effects associated with current HIV treatments, such as kidney toxicity and metabolic issues. The approach involves understanding the specific transport mechanisms of human concentrative nucleoside transporters and how they can be manipulated to improve drug efficacy and safety. Patients may benefit from new treatment options that are less toxic and more effective.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV/AIDS who are currently on nucleoside reverse transcriptase inhibitor therapies.
Not a fit: Patients who are not on nucleoside reverse transcriptase inhibitors or those with other unrelated health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective HIV/AIDS treatments with fewer side effects.
How similar studies have performed: Previous research has shown promise in optimizing nucleoside transport mechanisms, indicating potential for success in this novel approach.
Where this research is happening
North Chicago, United States
- Rosalind Franklin Univ of Medicine & Sci — North Chicago, United States (Active)
Researchers
- Principal investigator: Buolamwini, John K — Rosalind Franklin Univ of Medicine & Sci
- Study coordinator: Buolamwini, John K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.